AGN 2.78% 83.3¢ argenica therapeutics limited

AGN Media thread, page-131

  1. 22 Posts.
    lightbulb Created with Sketch. 1
    Lol reon1 if you say that the design covers all conditions and think the dose will be the same all for not having another phase 1 trial. Let’s focus on the current phase 2 trial, safety data expected in October and that will help the share price for sure
 
watchlist Created with Sketch. Add AGN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.